Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The first patients have been enrolled in The Medicines Company's pivotal phase III clinical trials evaluating cangrelor, a fast-acting, reversible, intravenous antiplatelet agent for preventing arterial thrombosis.
Subscribe to our email newsletter
If the trials are successfully completed and cangrelor receives regulatory clearance, the company believes cangrelor will be the first intravenous platelet inhibitor to market that binds directly to the P2Y12 receptor, a clinically validated target to treat or prevent arterial thrombosis in patients undergoing percutaneous coronary intervention (PCI).
The phase III program is comprised of two multinational trials to evaluate cangrelor’s effectiveness and safety in preventing ischemic events in patients who require PCI.
The first trial to enroll is called “Champion PCI” and has a planned enrollment estimated at 9,000 patients. The second trial, expected to begin in late 2006, is called “Champion Platform” and has planned enrollment estimated at 4,000 patients.
“Current antiplatelet therapies have limitations when used in patients with an acute presentation in the hospital setting. If the unique attributes cangrelor has previously demonstrated are confirmed, I believe cangrelor will be an important new therapeutic agent that will reshape the way we manage acute coronary thrombosis,” Dr Charles Pollack, chairman of the Department of Emergency Medicine, at Pennsylvania Hospital.